Clarivate Plc (CLVT) Earnings Call Transcript & Summary

November 3, 2026

New York Stock Exchange US Industrials Professional Services earnings 33 min

Earnings Call Speaker Segments

Mark Donohue

executive
#1

Thanks, and good morning to all of you. I appreciate you being with us on this Clarivate Third Quarter 2026 Earnings Conference Call. Just a note that this call is being recorded and webcast — and the content is copyrighted property of Clarivate. Rebroadcasting any of this information, whether fully or partially, without Clarivate's prior written consent is not allowed. You can find the earnings call presentation that goes with today's discussion in the Investor Relations section of the company's website. Over the course of this call, we may make certain forward-looking statements as defined under applicable securities laws. Those forward-looking statements carry known and unknown risks, uncertainties and other factors, and these could lead the actual results, performance or achievements of the business — or developments in Clarivate's business — to differ materially from the anticipated results, performance, achievements or developments expressed or implied by those forward-looking statements. Details on the factors that could make actual results or performance differ materially from what is anticipated are available in Clarivate's filings with the SEC and on the company's website. Our discussion will include non-GAAP measures, or adjusted numbers. Clarivate believes non-GAAP results are useful for enhancing understanding of our ongoing operating performance, but they are a supplement to GAAP financial measures and should not be considered in isolation from them or as a substitute for them. Reconciliations of these measures to GAAP measures can be found in our earnings release and supplemental presentation on our website. Joining me today are Matti Shem Tov, Chief Executive Officer; and Michael Easton, Chief Financial Officer. Once our prepared remarks are done, we'll open up the call to your questions. With that, it's a pleasure to hand the call over to Matti.

Matti Shem Tov

executive
#2

Thank you, Mark, and thanks to everyone for joining us. For Clarivate, Q3 marks a major step forward in the company's continuing transformation. We completed the strategic divestiture of the Life Sciences & Healthcare segment sooner than the planned schedule. With that done, Clarivate is now a more focused, higher-quality recurring business organized around 2 scaled, market-leading segments: Academia & Government and IP. Commercial momentum and customer validation are emerging from AI-led innovation in both segments. Web of Science Research Intelligence and IPOne are standout examples of that innovation being put into practice. I'll cover this in greater detail later. In Q2 we said the groundwork was in place for us to accelerate organic growth. The results this quarter show we have delivered on those commitments. Today's message is simple. We have a clear route to faster, durable organic growth, rising free cash flow and reduced leverage, and all of it will keep generating long-term value for shareholders. The Q3 figures reflect improved recurring revenue, strong profitability and cash generation, further debt reduction, and meaningful customer validation of our technology and AI capabilities. Organic ACV growth came in at 1.8%, 30 basis points higher than a year earlier. Bear in mind that this KPI serves as our forward-looking measure of organic revenue growth. Organic recurring revenue was up 1.3%, an improvement of 110 basis points versus the prior year. Within A&G, organic ACV and subscription revenue each rose roughly 2%. We're pleased that ABES in France picked Clarivate to upgrade its national academic library system. This multiyear deal will replace a legacy system with the unified Alma cloud-based platform, bringing together AI-driven discovery and library services across thousands of academic libraries and institutions. That is strong evidence of how large our platform is and how essential Clarivate is within the worldwide research ecosystem; in IP, recurring organic revenue climbed by just under 1%, and ACV returned to positive growth for the first time in over three years; among IP wins, the USPTO selected Clarivate to power image search across the U.S. trademark register, which places our image recognition capabilities inside a core trademark workflow. This highlights the value of combining trusted proprietary data, deeply embedded workflow solutions and AI to address our customers' mission-critical needs. Clarivate today is a scaled, focused business with substantial recurring revenue, at $2 billion of revenue and a 93% recurring organic revenue mix. Our portfolio contains three complementary models. Intelligent Solutions accounts for half of revenue, Workflow Solutions represents a quarter, and Technology-Enabled Services makes up the remaining 25%. Together, they give customers trusted decision support, embedded software, and expert-led services that they depend on for critical work around the world. AI is adding value across all of these offerings. Currently, we have more than 80 AI agents, assistants, and capabilities live in the market serving our customers — a figure that is growing at an accelerating pace — and these now reach 12% of our customer base. So far, our platform has processed over 465 million AI API calls — that's more than 2.5x what we saw at this same point a year ago. What this shows is how deeply AI is already running across Clarivate, though broad adoption is only one piece of the picture. What customers care about is whether we can bring AI to bear on trusted content and proven workflows while preserving trust, governance and quality — and that gives us even more reason to see AI as a major positive for our company. Let me now move to our two segments, beginning with Academia & Government and the strength of our position throughout the global research ecosystem. A&G is roughly a $1.2 billion business, about 95% recurring organic revenue, and its role is deeply woven into the worldwide research ecosystem. Our reach is considerable. Nearly all of the top 400 universities globally — 99% — depend on our solutions. More than 120 million students and researchers use our products to achieve better outcomes, and 75% of national and regional research assessments run on our data. Research, teaching and learning, funding decisions and library operations all have our solutions deeply embedded within them. What sets us apart is how we unite scholarly content and institutional workflows with research intelligence inside a proprietary ecosystem. That asset underpins a resilient recurring revenue stream and opens the opportunity to build new AI-enabled products. Web of Science Research Intelligence is a perfect illustration of exactly what I just described. Since launching in May, the platform has won more than 100 institutions across 25 countries. Crucially, for 2026 through 2027 we have built an active sales pipeline worth roughly $20 million, and we expect it to keep expanding. Through agentic AI, the platform helps institutions tackle complex research strategy, impact and funding questions, with results grounded in authoritative data curated by Clarivate; that matters because decisions made with our platform demand the highest standards of provenance, explainability and trust. Early customer traction worldwide reinforces our confidence in market adoption. The next step is clear: turn that customer interest and pipeline into recurring revenue at scale. In our view, these revenue opportunities are incremental and also support even stronger retention for Web of Science. Turning to Intellectual Property. Our other large segment is IP, bringing in $800 million in revenue, 90% of which is recurring organic revenue, and it supports the global IP ecosystem. Solutions from our company are used by 90% of the top 100 R&D investors. Over 15,000 IP customers count on Clarivate to manage and safeguard their portfolios, and 40 patent and trademark offices rely on our solutions, including the 5 largest in the world. The work we support is nondiscretionary and nondeferrable. Customers depend on Clarivate to create, protect, manage and commercialize intellectual property around the world and to safeguard billions of dollars of intangible value with certainty and continuity. Importantly, the fundamentals of this business are improving, and we're seeing roughly 12% growth in that area. Recurring organic revenue was up almost 1% during Q3, and ACV came back to positive growth. That shows we're making continued progress and demonstrates that our commitments are being delivered on. Our competitive distinction comes from the way we combine our IP management software, our curated patent and trademark data, our lifecycle services, and one of the largest teams of IP specialists in the industry. That same combination provides a firmer foundation for launching the next generation of AI agentic platform. IPOne is the thing that turns that strategy into reality. IPOne is developing into an AI-native intelligence layer that spans the IP lifecycle, bringing together specialized agents, cloud, proprietary data and trusted intelligence. Its grounding is customers' proprietary IP data held within Clarivate software, which general-purpose AI is unable to reach. From where we sit, IPOne can act as the intelligence and agentic foundation across the IP lifecycle. As we get ready for the November early adopter launch, we are working with more than 40 development partners across 25 countries, including over 15 Fortune Global 500 companies. A live sales pipeline of 151 customers is already in place, and we expect that figure to rise over the months ahead. The initial release is expected to include 5 purpose-built AI agents along with a growing library of agentic workflow skills; these are built on more than 1 billion interconnected data points that Clarivate has assembled and enriched over decades, with help from our IP domain experts. By launching IPOne, we expect to create new revenue streams and improve subscription retention, and it already accounts for 12% of our pipeline. Let me tie this together. We have taken deliberate steps to improve the quality and performance of Clarivate. Our strategy is working. We have increased the recurring revenue mix of the business, sharpened our commercial execution, accelerated product innovation, streamlined the portfolio and reduced debt. And increasingly, these steps are reflected in our KPIs. Recurring revenue growth is recovering. IP ACV is growing again, and our new AI-led platforms are attracting customers and building commercial pipelines. Given the sale of Life Sciences & Healthcare, we wanted to offer an early view of 2027. The current target is to deliver stronger organic ACV and recurring revenue growth along with higher free cash flow and lower net leverage. We look forward to providing full 2027 guidance in February. One last point I want to leave with you. Clarivate today is not the same company that began this transformation when I joined as CEO 2 years ago. With that, Michael will take you through our financial results in more detail.

Michael Easton

executive
#3

Thanks, Matti. We keep pushing our growth agenda forward, concentrating the portfolio around scaled products that generate recurring revenue. It's encouraging to see IP get back to positive recurring organic revenue growth this quarter, and organic subscription revenue growth continues in A&G. On Slide 14, there's a summary of our Q3 and year-to-date results alongside the same period a year ago. As a reminder, the third quarter and year-to-date financials took a hit from the October 2026 divestiture of the LS&H segment, so LS&H results now appear as discontinued operations in every period shown. In the earnings presentation's waterfall schedules, we've presented discontinued operations separately, letting you see how continuing operations performed and compare against figures reported earlier. Q3 revenue from continuing operations came to $482 million, bringing the year-to-date total to nearly $1.5 billion. The quarterly change from the prior year stemmed from inorganic disposals, and the 5% year-to-date decline versus last year came entirely from inorganic disposals—specifically the A&G books business. As a reminder, that wind down finished in this year's second quarter, so the impact will anniversary during the back half of 2027. Continuing operations posted a $26 million loss in Q3, essentially unchanged from a year earlier, while adjusted EBITDA was level for the first nine months and essentially level for the quarter despite the drag from divestitures. Third-quarter adjusted diluted EPS rose $0.03 from the prior year to $0.21, bringing the year-to-date figure to $0.59 — a 20% increase compared with the same stretch last year. Cash from operations was $166 million during the quarter. Versus last year, the shift reflected lower adjusted EBITDA from the disposals, plus higher tax and working capital needs tied to the timing of receipts and disbursements, partly offset by lower interest expense. Let's turn to Page 15, where we'll look at what drove the third quarter's top and bottom-line changes versus the prior year. Three main factors drove the continuing operations changes over the prior year. First, recurring organic revenues increased $6 million, or 1.3%, which was offset by a decline in transactional revenues, giving total organic revenue growth of $2 million, or 0.4%; that's our strongest recurring revenue growth in more than a year and keeps us on track to improve this metric by 100 basis points from H1 to H2. The revenue growth, along with cost efficiencies, produced organic flow-through to profit of $13 million. Additionally, revenue from the operations we're divesting dropped by $48 million, which had a 25% effect on profit, stemming almost wholly from winding down the A&G books business. During Q3, we also chose to discontinue a few smaller transactional products with low margins, largely within the IP segment—accounting for roughly 1% of overall revenue and a negligible profit contribution—and these discontinuations will take place across the coming 1 to 2 years. And lastly, foreign exchange had only a minor effect on the top line, but its impact on profit was bigger, since the U.S. dollar weakened against the basket of foreign currencies, and we also had realized transaction losses. To sum up, getting back to organic revenue growth, along with strategic disposals and disciplined cost management, enabled us to raise adjusted EBITDA margin by more than 300 basis points compared with the same period a year ago. Now please go with me to Page 16, where we run the same analysis on the first 3 quarters of the year. Recurring organic revenue growth year-to-date of $12 million, or almost 1%, was mostly offset by how transactional revenue performed, but cost discipline fully offset that effect, producing an organic contribution of $22 million to adjusted EBITDA. Revenue fell by $85 million because of the disposals, yet since those carry low margin, adjusted EBITDA was down by just $13 million. In the same period last year, the U.S. dollar was weaker against a basket of foreign currencies, which gave revenue a foreign exchange lift but weighed on profit through currency effects on costs, plus transaction gains that did not recur this year. All told, recurring revenue growth, strategic disposals and disciplined cost management delivered 200 basis points of margin expansion across the first 3 quarters of the year — a improving trend we expect to carry into the fourth quarter. Turning to Page 17, you'll see how we get from our adjusted EBITDA to free cash flow, and how we keep deploying capital prudently to make the balance sheet even stronger. In the third quarter, free cash flow came to $110 million, down $5 million from the prior-year period. That decline comes from higher taxes and working capital—mostly tied to collection and payment timing—partly offset by lower interest and capital expenditures. We put that free cash flow toward buying back an additional $75 million of notes maturing in 2028 at roughly a 2% discount, bringing debt reduction so far this year to $293 million. Let's go to Page 18, where you can see the ranges we're guiding to for the full year. We discussed this back in the second quarter: now that the divestiture has closed, we're revising guidance because LS&H is out of our financial results. The new ranges for revenue, adjusted EBITDA, and the associated metrics exclude LS&H results for every period this year, since those results are now accounted for as discontinued operations. As a reminder to everyone, back in early July 2026, when we announced the deal to sell LS&H, we gave full-year 2026 projections for that segment of $370 million in revenue and $120 million in adjusted EBITDA, and as in past years, that was weighted toward the fourth quarter on a seasonal basis. With three quarters of the year now behind us, we're also narrowing the full-year guidance ranges. And to give a clearer picture of the ongoing business, we've included fourth-quarter guidance ranges in the earnings release. When it comes to organic ACV, we're looking at something in the 1.75% to 2.25% range, and I should note that ACV in our IP segment came back to positive organic growth during Q3. Across the full year, we expect recurring organic revenue to rise by 1% to 1.5%, and Q4 in particular should exceed 2%. Our revenue guidance is now $1.965 billion to $1.985 billion, and the year-over-year decline there is driven completely by the intentional strategic wind down of the A&G books business. That wind down finishes in the second quarter of 2026, so we expect total revenue comparisons to turn favorable year over year in the back half of 2027. Recurring revenue, notably, will now make up 92% to 94% of our mix. For the full year, we now expect adjusted EBITDA to grow positively, coming in at $865 million to $885 million. All of that profit improvement should land in Q4. At the midpoint, adjusted EBITDA margin should be close to 44%. In connection with this, $23 million, $33 million, and 2020.

Michael Easton

executive
#4

We still expect adjusted EPS to rise about 9% at the midpoint of the range, getting to $0.75. Also, we've changed our free cash flow guidance to a range of $320 million to $340 million, because we've now taken on the full transaction costs — roughly $30 million — tied to closing the divestiture, and we won't get the benefit of seasonally stronger LS&H free cash flow in the fourth quarter. As for 2027, we're looking for free cash flow growth of 10% to 15%. Now let's turn with me to Page 19 and go over the full year top and bottom line changes we expect compared with last year. For adjusted EBITDA margin, we're looking at an increase exceeding 250 basis points, driven by organic growth coming back, continued discipline on costs, and the strategic disposals being finished. Total organic revenue growth should come in at about 50 basis points, with subscription revenue growth—arising from ongoing ACV acceleration—leading the way. Our plan for cost efficiencies has been delivered, producing $40 million of organic growth, and that will drive most of the margin expansion. When it comes to inorganic divestitures, those should lower revenue by around $110 million in the current year, while we're also reducing operating expenses by roughly $90 million—together that yields a profit effect of about $20 million. The remaining portion of the full-year revenue and profit impact stems from movements in foreign currency exchange rates. Now let's move to Page 20, where I'll take you through the improvement we anticipate this year in revenue, KPIs and margin, which we've refreshed to reflect results so far this year. Momentum in our quarterly performance keeps building. And as we noted during our second quarter earnings, we continue to expect recurring organic revenue growth for H2 to come in 100 basis points better than H1. For Q4, we expect recurring organic growth to exceed 2%, which would mark our strongest quarter in over three years and position us favorably going into 2027. Organic growth, cost efficiencies we've implemented, and gains from the strategic disposals should keep profit margins above 45% in Q4. Total revenue will also be higher in Q4, driven by the usual cadence of patent and trademark renewals along with improving organic ACV and recurring revenue growth. Let's go to Page 21, where we'll look at how we anticipate adjusted EBITDA turning into free cash flow, and how we intend to use that capital—together with the divestiture proceeds—to bring our debt down by roughly $875 million this year. Our current expectation is that free cash flow will come in at around $330 million for the year, since we've now booked all transaction costs related to closing the divestiture, and we won't have the seasonally stronger LS&H free cash flow in the fourth quarter. Most of the onetime cost, roughly $70 million, won't repeat next year. Our current projection is that cash interest will come in roughly $25 million lower than a year ago, reflecting debt that was repaid during the last year and this one. Within this year, we anticipate working capital moving in a direction that consumes approximately $35 million, mostly driven by payments for incentive compensation. Investment in product innovation remains a priority for us, and the LS&H divestiture in October 2026, together with the disposals and cost efficiencies, ought to free up about $35 million in capital spending. On capital allocation, we intend to use the proceeds from the LS&H divestiture to buy back at a discount some of the notes maturing in 2028 and 2029. The third quarter marked a major milestone for the company, since we finished a key move toward concentrating on our two scaled segments and continued advancing our VCP plan — generating growth, bettering cash flow, reinforcing our capital structure and building shareholder value. Operator, let's turn now to the Q&A portion.

Brandon Cohen

analyst
#5

Brandon Cohen here, filling in for Manav Patnaik. Regarding ACV, you cited pricing as the main factor behind the 1.8% growth posted this quarter. Could you please break down the price versus volume dynamic a bit more? And what precisely has to occur for retention and new subscription sales to drive more of the acceleration as we head into Q4 and into 2027?

Matti Shem Tov

executive
#6

Michael, go ahead.

Michael Easton

executive
#7

Yes. Brandon, thanks for asking that. We feel good about how ACV performed this quarter, coming in at 1.8%. As we've mentioned, pricing is one of the main things driving that. We've discussed this before — we aim to land at or near 3% on pricing. Pricing has stayed steady and robust throughout this year, and on volumes we keep seeing gains on an overall basis. Our target now is to finish the year with 2% ACV growth, which means another step up from Q3 to Q4 and then more progress as we head into 2027, as Matti mentioned.

Keen Fai Tong

analyst
#8

This is Alex Later on, speaking for George Tong. For the first time in over 3 years, ACV went back to positive growth, even as total segment organic revenue fell 0.4%. Could you talk about what is behind that ACV improvement and how you expect it to carry through into organic revenue growth going forward?

Matti Shem Tov

executive
#9

Well, to start, let's keep in mind how strong the IP business is; the work we support is nondiscretionary and nondeferrable; we are — we form part of this broader IP ecosystem. We've been through quite a lot in IP. Management has now been stabilized; our sales organization team is far more focused, we have recurring revenue growth of 1%, a return to positive ACV growth; Simon is now running the business in a tighter way, and we are also very, very pleased with how we are positioned around IPOne. We're very confident that IPOne is the right layer to help us not only with new ACV, but also to help us on the retention side for the recurring revenue side; so we're very — we learned a great deal in IP through the management transition, we are bringing out new products and the type of sales organization, and it's very positive to believe IP is coming by.

Abe Landa

analyst
#10

You mentioned something about using the LS&H proceeds to repay the '28s and '29s at a discount. Could you maybe walk through how you plan to do that?

Michael Easton

executive
#11

Yes. Thanks for the question. As we disclosed, over the course of this year we've bought back roughly $290 million of debt so far year-to-date; that's been at a discount ranging from 2% to 3% in the second quarter and the third quarter. And for the fourth quarter, our plan would be to approach it the same way we've done the buybacks in the third quarter and the second quarter. So really no change from that, and we'll look for the right opportunity to start the process and look to complete that in relatively short order here in the fourth quarter.

Abe Landa

analyst
#12

So how do you think about repurchasing the '28s compared with the '29s, given that they mature at different times? And perhaps how do you view your capital structure over the longer term?

Michael Easton

executive
#13

Yes. No, you're right. I mean, there is a clear distinction between the two. Those are the 2 notes coming due in the near term. So we essentially weigh that opportunity against the timing of when those notes mature, what we believe is the appropriate capital allocation approach between the 2, and obviously we look to our cash proceeds and free cash flow so we can retire them in due course before they arrive or become current.

Matti Shem Tov

executive
#14

To wrap up, I'd say the progress makes us proud, and we feel confident about what lies ahead. Execution is what we're focused on now — turning that foundation into faster, sustained organic growth, growing free cash flow, and bringing our leverage down. Thanks for being with us today.

Operator

operator
#15

This concludes today's call. Thank you for attending. You may now disconnect.

Read the full transcript via the API

You're viewing the first half of this call. Get the complete Clarivate Plc transcript — plus 132,000+ transcripts from 7,000+ companies, speaker segments, AI summaries and full-text search — through the EarningsCalls.dev API.

Get the API View API docs →

This call discussed

For developers and AI pipelines

Programmatic access to Clarivate Plc earnings transcripts and 132,000+ others is available through the EarningsCalls.dev REST API. Plans from $39.99/month — full transcripts, speaker segments, full-text search, and the recently-added /api/v1/transcripts/recent polling endpoint for ETL pipelines.

More tools for stock research

OptionsBell: an unusual options activity scanner that tracks options flow across all US stocks and emails you when large trades appear in Clarivate Plc or any ticker on your watchlist.

StockMarketScan: a stock screener with alerts: 24 pre-built screens refreshed every 5 minutes, watchlists and email notifications. Both offer API and MCP access and fair monthly pricing.